Adenovir Pharma is developing a topical drug for the treatment of epidemic keratoconjuntivitis (EKC). Caused by adenoviruses, millions of people are infected every year by (EKC). There are currently no effective treatments.
Based on the successful Phase I results, Adenovir Pharma is now planning a Phase II study in Europe. The phase I study included 48 healthy volunteers: 24 subjects in Part A single dose and 24 subjects in Part B multiple dose and showed that Adenovir Pharma’s drug candidate APD -209 is safe and well tolerated.
”To have completed the first study in human is a very important phase for the project. The results show that APD-209 is safe and well tolerated, which is in line with the expectations from preclinical studies. We are now planning a Phase 2a-study in patients with EKC and are actively recruiting potential investigators in the EU”, said Björn Dellgren, project leader of Adenovir Pharma.
In July this year, Adenovir Pharma raised SEK 9.6 million. The capital injection will be used for ongoing product development and pre-clinical and clinical studies. Major financiers include P.U.L.S. AB, BWG Holding, Länsförsäkringar Skåne, Sparbanksstiftelsen Skånes Riskkapitalstiftelse, and Augmenta.
Adenovir Pharma is a project company of the life science incubator P.U.L.S. AB, based in Helsingborg, Sweden. The research origins from the virology department at Umeå University, and from the organic chemistry department at Lund University.